Next generation pan-serotype, antitoxin for botulinum neurotoxin exposures - botulinum neurotoxins (BONTS) inactivate motor neurons with extraordinary potency causing flaccid paralysis, breathing…
Active Grant Awarded
- Award ID
- R61AI197779
- Recipient
-
Trustees Of Tufts College UEI C1F5LNUF7W86
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $531,688
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 25% complete
- Place of performance
- North Grafton, MA 01536, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $531,688 on May 19, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The award funds development of a next-generation pan-serotype antitoxin for botulinum neurotoxin exposures, built from heteromultimers of linked camelid single-domain antibodies (VHHs) and delivered as formulated RNA across an R61/R33 two-phase structure. Ultimate completion is May 31, 2028, and the place of performance is North Grafton, Massachusetts.
Wake Forest University Health Sciences received a sub-award dated June 29, 2026 to challenge mice and guinea pigs with botulinum neurotoxin serotypes A through G and assess antitoxins delivered as protein or formulated RNA. In the R61 phase, the sub-recipient optimizes pharmacokinetics, route of administration, and VHH selection for serotypes C, D, F, and G. In years one and two, it runs neutralization assays on approximately 96 VHHs and 12 VNAs, and in years three through five it conducts proof-of-efficacy studies.
HDT Bio Corp received a sub-award dated July 10, 2026 to produce replicating RNA constructs expressing novel VNAs during the R61 phase and to perform product and process development in the R33 phase. That work includes designing multivalent replicating RNAs against all seven BoNT serotypes, RNA manufacturing and purification, formulation and drug product mixing, and assessment of pharmacokinetic and safety parameters in mice. HDT also ships therapeutic RNAs to participating laboratories for efficacy testing.
Description
Next generation pan-serotype, antitoxin for botulinum neurotoxin exposures - botulinum neurotoxins (BONTS) inactivate motor neurons with extraordinary potency causing flaccid paralysis, breathing difficulties and often death. As such, BONTS are among the most dangerous tier 1 biothreat agents, and in addition, cause significant death and illness from botulism poisoning obtained from contaminated foods. The few available botulism treatments derive from polyclonal antisera produced in large animals, such as the equine botulism antitoxin 'BAT'. Such products are often associated with multiple commercial challenges and potential health risks. The bont antitoxins are centrally stockpiled which often causes significant delays in the time to treatment, thus reducing or even obviating their efficacy as they must be administered before the circulating toxin has entered neurons. Our strategy for a next generation bont antitoxin product is to employ heteromultimers of linked antitoxin camelid single-domain antibodies (vhhs or nanobodies), likely administered encoded as formulated RNA. Our RNA products will permit economic manufacturing and distributed stockpiling, thus reducing time to treatment and improving efficacy. We have previously shown that heteromultimeric VHH- based neutralizing agents (VNAS) containing six VHH components can have high potencies equivalent to or greater than those of complex polyclonal antisera or conventional monoclonal antibody antitoxin products. Furthermore, VNA products offer exceptional versatility in product design. Formulated RNA products have been amply demonstrated as safe, rapidly responsiveness to new threats and rapidly and economically manufactured at large scale. In our studies, we have shown that a single protein VNA or a formulated RNA/VNA product can provide potent antitoxin protection from at least three different botulism serotypes in toxin exposed animals. In the R61 phase of this R61/R33 proposal, we will use our robust computational VHH discovery tools together with detailed characterization of binding structures to complete the discovery of VHH components that broadly bind and neutralize all known natural subtypes of the seven bont serotypes. In the R33 phase, we will create one or two VHH heteromultimeric VNAS and test their ability to provide potent protection from all natural subtypes of the seven bont serotypes. We will perform extensive process and product development activities for a VNA drug product and perform IND-enabling studies, including testing efficacy in mouse and guinea PIG models of bont intoxication. If successfully completed, we will have demonstrated the feasibility of a next-generation antitoxin product to replace the current, outdated, polyclonal bont antitoxin and be in position to rapidly commercialize the new product. Also important, the technologies we develop should have broad application in creating practical and effective antitoxin therapeutics for many currently untreated or ineffectively treated toxin- mediated diseases.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| HDT Bio Corp | $37,414 | |
| Wake Forest University Health Sciences | $138,615 |
Quick answers
Who received award R61AI197779?
R61AI197779 was awarded to Trustees Of Tufts College by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 19, 2026.
How much is award R61AI197779 worth?
$531,688 has been obligated on R61AI197779.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award